2014 Press Releases

Webcast ImageWebcast
Chromadex Corp at the 11th Annual LD Micro Main Event (Replay)
12/05/18 at 4:30 p.m. PT
Chromadex Corp at the 11th Annual LD Micro Main Event
Wednesday, December 5, 2018 4:30 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
12/10/14NIH Publishes Results of Preclinical Collaboration with ChromaDex Showing Potential Benefit of Nicotinamide Riboside
- NR Studied as a Treatment for Premature Aging in Cockayne Syndrome and Age Related Neurodegeneration - IRVINE, Calif., Dec. 10, 2014 /PRNewswire/ -- ChromaDex Corp.  (OTCQX: CDXC), announced today that the results of a mouse study performed in collaboration with ChromaDex by the National Institute on Aging (NIA), a member of the National Institutes of Health (NIH), were published in Cell Metabolism in November 2014. The results indicated that nicotinamide riboside (NR) was effective at re... 
Printer Friendly Version
12/04/14ChromaDex® CEO to Present at The Benchmark Company, LLC's Micro Cap Discovery One-on-One Conference on Dec. 11
IRVINE, Calif., Dec. 4, 2014 /PRNewswire/ -- ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at The Benchmark Company, LLC's Micro Cap Discovery One-on-One Conference on Thursday, Dec. 11, 2014, located at the Palmer House Hilton in Chicago. Mr. Jak... 
Printer Friendly Version
12/03/14ChromaDex® Receives $750,000 Cash from Previous Sale of its BluScience™ Line
IRVINE, Calif., Dec. 3, 2014 /PRNewswire/ -- ChromaDex® Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it has received a cash payment of approximately $750,000 for the shares of NeutriSci International Inc. ("NeutriSci"), that the company received as part of its prior transaction with NeutriSci. In March 2013,... 
Printer Friendly Version
12/02/14ChromaDex Licenses Exclusive Worldwide Patent Rights from the University of Mississippi for Microalgae Technology Targeting Immune Support
IRVINE, Calif., Dec. 2, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has licensed exclusive worldwide rights from the University of Mississippi for several patents related to the isolation and use of immunostimulatory extracts from microalgae. The exclusive worldwide ... 
Printer Friendly Version
11/24/14ChromaDex Announces Two Patent Issuances for Novel Ingredient, Pterostilbene
IRVINE, Calif., Nov. 24, 2014 /PRNewswire/ -- The U.S. Patent and Trademark Office has granted patent #8,809,400 B2 (referred to as the '400 patent) and #8,841,350 B2 (referred to as the '350 patent) pertaining to the ingredient pterostilbene, both of which are licensed exclusively to ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and phar... 
Printer Friendly Version
11/17/14University of Birmingham Receives Grant from Wellcome Trust to Support Human Research on ChromaDex's NIAGEN® Nicotinamide Riboside
IRVINE, Calif., Nov. 17, 2014 /PRNewswire/ -- ChromaDex Corp.  (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the University of Birmingham, whereby it will provide quantities of its patented NIAGEN® nicotinamide riboside for pre-clinical and human s... 
Printer Friendly Version
11/12/14Animal Study Confirms Results of ChromaDex Human Clinical Study on Weight Loss with Pterostilbene
-Recently Published Study Shows Pterostilbene Impacts Body Fat and Obesity- IRVINE, Calif., Nov. 12, 2014 /PRNewswire/ -- A recent study led by Saioa Gomez-Zorita published in the Journal of Agricultural and Food Chemistry has demonstrated the weight loss effects of pterostilbene in rats fed an obesogenic diet. The study confirms the results of a 2012 human clinical trial on the effect of pterostilbene on weight loss conducted by ChromaDex (OTCQX: CDXC), an innovative natural products... 
Printer Friendly Version
11/07/14ChromaDex to Begin Trading on OTCQX Marketplace on November 10
IRVINE, Calif., Nov. 7, 2014 /PRNewswire/ -- ChromaDex®Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today it has received approval for its common stock to trade on OTCQX®, the best marketplace for established global and growth companies.  Trading on OTCQX will begin on Monday, November 10, 2014 under the Company's existi... 
Printer Friendly Version
11/06/14ChromaDex® Reports Ingredient Sales Grew 160% in the Third Quarter
IRVINE, Calif., Nov. 6, 2014 /PRNewswire/ -- ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today the financial results for the quarter ended September 27, 2014. For the three months ended September 27, 2014 ("Q3 2014"), the Company reported net sales of $4,139,710, an increase of approximately 52% as compare... 
Printer Friendly Version
10/06/14New Edition of the Hayes' Principles and Methods of Toxicology Provides Critical New Chapter on Food Safety and Foodborne Toxicants
IRVINE, Calif., Oct. 6, 2014 /PRNewswire/ -- ChromaDex Corp.  (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, has announced that two leaders of its Spherix Consulting affiliate, A. Wallace Hayes, Ph.D., senior science advisor, and Claire Kruger, Ph.D., president, served as editors for the sixth edition of the influential textbook, Hayes' Pr... 
Printer Friendly Version
10/01/14Life Extension Introduces a New Anti-Aging Supplement, NAD+ Cell Regenerator™, Featuring NIAGEN™
IRVINE, Calif., Oct. 1, 2014 /PRNewswire/ -- ChromaDex Corp.  (OTCQB: CDXC), Life Extension announced today the launch of NAD+ Cell Regenerator™, an innovative nutritional supplement that boosts vitality and supports healthy aging.  NAD+ Cell Regenerator™ features the ingredient NIAGEN™ from ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic a... 
Printer Friendly Version
09/30/14ChromaDex Secures $5.0 Million in Growth Capital Financing from Hercules
IRVINE, Calif., Sept. 30, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it closed on a $5.0 million growth capital debt financing from Hercules Technology Growth Capital (NYSE: HTGC).  The financing will provide ChromaDex with additional working capital to support its rapidly-growi... 
Printer Friendly Version
09/22/14University of California Irvine Completes Pterostilbene Study For Prevention of Skin Damage from UV Exposure
- ChromaDex Licensed Exclusive Rights to Several Patent Applications for Use of Pterostilbene in Topical Skin Care Applications - IRVINE, Calif., Sept. 22, 2014 /PRNewswire/ -- ChromaDex Corp.  (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the completion of an animal skincare study of pterostilbene by r... 
Printer Friendly Version
09/11/14ChromaDex and Healthy Directions enter into NIAGEN™ Supply Agreement
IRVINE, Calif., Sept. 11, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today that it has entered into an ingredient supply agreement with Healthy Directions, a direct-to-consumer nutritional supplement retailer and wholly-owned subsidiary of Helen of Troy Limited (NASDAQ: HELE). ChromaDe... 
Printer Friendly Version
09/04/14ChromaDex Names Additional Scientific Advisory Board Members
- Company's Scientific Advisory Board Will Comprise a Diverse Range of Experts with an Emphasis on Nicotinamide Riboside - IRVINE, Calif., Sept. 4, 2014 /PRNewswire/ -- ChromaDex Corp.  (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, announced today it has appointed three highly respected scientists and researchers to the company's rec... 
Printer Friendly Version
08/12/14ChromaDex® Reports Second Quarter Ingredient Sales Grew 155% Year-Over-Year and 52% Sequentially
IRVINE, Calif., Aug. 12, 2014 /PRNewswire/ -- ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the quarter ended June 28, 2014. For the three months ended June 28, 2014 ("Q2 2014"), the Company reported net sales of $3,856,154, an increase of approximately 42% as c... 
Printer Friendly Version
08/06/14ChromaDex's Ryan Dellinger to Speak at 248th American Chemical Society National Meeting
Director of Scientific Affairs will present details of the clinical evaluation of ChromaDex's PURENERGY® caffeine alternative IRVINE, Calif., Aug. 6, 2014 /PRNewswire/ -- ChromaDex Corp.  (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that Ryan Dellinger, Ph.D., director of scientific affairs at ChromaDe... 
Printer Friendly Version
08/05/14ChromaDex® CEO to Present at 34th Annual Canaccord Genuity Growth Conference on August 13th at 8:30 am EDT
IRVINE, Calif., Aug. 5, 2014 /PRNewswire/ -- ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 34th Annual Canaccord Genuity Growth Conference to be held at the Intercontinental Boston. Mr. Jaksch will present on Wednesday, August 13th at 8:30 ... 
Printer Friendly Version
07/31/14ChromaDex Signs Material Transfer Agreement With Prominent Australian Research Institute for NIAGEN™ Research
- NIAGEN™ is the first and only commercially available Nicotinamide Riboside - IRVINE, Calif., July 31, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with Murdoch Childrens Research Institute, the preeminent chi... 
Printer Friendly Version
07/16/14ChromaDex Initiates First Human Clinical Study to Confirm ChromaDex's NIAGEN™ Nicotinamide Riboside Will Increase NAD+
- ChromaDex's Patented NIAGEN™ Is the First and Only Commercially Available Nicotinamide Riboside - IRVINE, Calif., July 16, 2014 /PRNewswire/ -- ChromaDex Corp.  (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the initiation of the first human clinical study for its patented ingredient NIAGEN™, the... 
Printer Friendly Version
07/08/14Nobel Laureate Roger Kornberg to Chair New ChromaDex Scientific Advisory Board
- Company's Scientific Advisory Board Will Be Comprised of a Diverse Range of Experts with an Emphasis on Nicotinamide Riboside - IRVINE, Calif., July 8, 2014 /PRNewswire/ -- ChromaDex Corp.  (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has appointed Nobel Laureate Roger Kornberg to Chair the Compan... 
Printer Friendly Version
06/19/14ChromaDex Signs Collaboration Research Agreement with St. Jude Children's Research Hospital
IRVINE, Calif., June 19, 2014 /PRNewswire/ -- ChromaDex Corp.  (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a joint collaboration agreement with St. Jude Children's Research Hospital to evaluate ChromaDex's natural product libraries. The collaboration between ChromaDex and St. Jude w... 
Printer Friendly Version
06/03/14ChromaDex Licenses Exclusive Patent Rights from Dartmouth College for Pharmaceutical Use of Nicotinamide Riboside (NR)
IRVINE, Calif., June 3, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has licensed exclusive rights from Dartmouth College for several patents related to pharmaceutical use of nicotinamide riboside (NR).  The new licensed patents include protection for human therapeuti... 
Printer Friendly Version
05/30/14/C O R R E C T I O N -- ChromaDex Corporation/
In the news release, ChromaDex CEO to Present at the Jefferies 2014 Global Healthcare Conference, issued 30-May-2014 by ChromaDex Corporation over PR Newswire, we are advised by the company that the financial table at the end of the release should not be included. The complete, corrected release follows: ChromaDex CEO to Present at the Jefferies 2014 Global Healthcare Conference IRVINE, Calif., May 30, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products com... 
Printer Friendly Version
05/30/14ChromaDex CEO to Present at the Jefferies 2014 Global Healthcare Conference
IRVINE, Calif., May 30, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that Frank L. Jaksch, Jr., founder and CEO of ChromaDex, will present at the Jefferies 2014 Global Healthcare Conference in New York on Tuesday, June 3, 2014, at 2:00 p.m. EDT. In addition to his p... 
Printer Friendly Version
05/28/14ChromaDex and JQMS Announce Exclusive Sales and Marketing Agreement for GMP Compliance Services
IRVINE, Calif., May 28, 2014 /PRNewswire/ -- ChromaDex Corp.  (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, and Joy's Quality Management Systems, Inc. (JQMS), a leading consulting firm for  regulatory compliance and training services, announced today that ChromaDex has been designated as the exclusive sales and marketing ag... 
Printer Friendly Version
05/14/14ChromaDex® CEO to Present at 15th Annual B. Riley Conference on May 19th at 9:30 am PDT / 12:30 pm EDT
IRVINE, Calif., May 14, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 15th Annual B. Riley & Co. Investor Conference to be held at May 19th – 21st at the Loews Santa Monica Beach Hotel in Santa Monica, CA. Mr. Jaksch... 
Printer Friendly Version
05/13/14ChromaDex Initiates Second Human Clinical Study for its Caffeine Ingredient, PURENERGY®
- Company expects numerous retail products to be launched in 2014 that incorporate PURENERGY® as an alternative ingredient to caffeine - IRVINE, Calif., May 13, 2014 /PRNewswire/ -- ChromaDex Corp.  (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the initiation of the second human clinical study for PUREN... 
Printer Friendly Version
05/08/14ChromaDex® Reports 32% Increase in First Quarter Revenue as Ingredient Sales Grow 97%
IRVINE, Calif., May 8, 2014 /PRNewswire/ -- ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the quarter ended March 29, 2014. For the three months ended March 29, 2014 ("Q1 2014"), the Company reported net sales of $3,074,138, an increase of approximately 32% as c... 
Printer Friendly Version
05/05/14ChromaDex Signs Material Transfer Agreement With Wageningen University for NIAGEN™ Research
-- NIAGEN™ is the first and only commercially available Nicotinamide Riboside -- IRVINE, Calif., May 5, 2014 /PRNewswire/ -- ChromaDex Corp.  (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the Wageningen University in the Netherlands. ChromaDex... 
Printer Friendly Version
04/23/14UM Technology Management Division and Research Partners Land National Award
Technology transfer prize honors work to develop, study and bring pterostilbene to market OXFORD, Miss. and IRVINE, Calif., April 23, 2014 /PRNewswire/ -- A collaboration formed by the University of Mississippi's Division of Technology Management, the USDA Agricultural Research Service's Natural Products Utilization Research Unit and natural products company ChromaDex Corp. (OTCQB: CDXC) has won a national award for excellence in technology transfer. The three organizations have won a Fe... 
Printer Friendly Version
04/23/14ChromaDex Provides Update on $62 Million Ingredient Agreement with Network Marketing Company 5LINX®
- 5LINX® To Launch New Product Suite Featuring ChromaDex's Patented NIAGEN™ Nicotinamide Riboside and PURENERGY® at Annual Event in May - IRVINE, Calif., April 23, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, provided an update today on its pre... 
Printer Friendly Version
04/16/14ChromaDex CEO, Frank Jaksch, to Speak at 13th Annual Oxford International Conference on the Science of Botanicals
IRVINE, Calif., April 16, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its founder and CEO, Frank Jaksch, will speak at the 13th Annual Oxford International Conference on the Science of Botanicals on April 15th to 17th, 2014. Mr. Jaksch, who will present on Wedne... 
Printer Friendly Version
04/15/14ChromaDex Signs Material Transfer Agreement With University of Copenhagen for NIAGEN™ Nicotinamide Riboside Research
IRVINE, Calif., April 15th, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the Novo Nordisk Foundation Center for Basic Metabolic Research at University of Copenhagen, Denmark. ChromaDex will provide the Universi... 
Printer Friendly Version
04/07/14ChromaDex Signs Collaboration Research Agreement with Brazilian Research Institute
IRVINE, Calif., April 7, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB:CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a joint collaboration agreement with Brazilian Biosciences National Laboratory (LNBio) to evaluate ChromaDex's natural product libraries. ChromaDex and LNBio are establishing a co... 
Printer Friendly Version
04/02/14Thorne Research Introduces a New Product, NiaCel™, Featuring NIAGEN™, To Support Healthy Aging
IRVINE, Calif., April 2, 2014 /PRNewswire/ -- Thorne Research today announced the launch of NiaCel™, an innovative nutritional supplement that supports endurance, energy, and healthy aging.  NiaCel™ is one of the first commercially available products to feature the ingredient NIAGEN™ from ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic, and... 
Printer Friendly Version
03/27/14ChromaDex® Reports 2013 Full-Year Results
IRVINE, Calif., March 27, 2014 /PRNewswire/ -- ChromaDex® Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the year ended December 28, 2013. For the year ended December 28, 2013 ("FY 2013"), the Company's combined core standards, contract services, scientific and regulatory c... 
Printer Friendly Version
03/12/14ChromaDex Signs Material Transfer Agreement With Leading Dutch University for NIAGEN™ Research
-- NIAGEN™ is the first and only commercially available Nicotinamide Riboside -- IRVINE, Calif., March 12, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a material transfer agreement (MTA) with the Groningen Biomolecular Sciences & Biotechnolo... 
Printer Friendly Version
03/06/14ChromaDex to Present at the 26th Annual ROTH Conference on March 10th at 4:30 pm PDT
IRVINE, Calif., March 6, 2014 /PRNewswire/ -- ChromaDex Corp.® (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 26th Annual ROTH Conference, which will take place from March 9-12 at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.  Mr. Jaksch will present... 
Printer Friendly Version
01/06/14ChromaDex® Announces $62 Million Ingredient Agreement with Network Marketing Company 5LINX®
- Four Year Deal is for ChromaDex's NIAGEN™ Nicotinamide Riboside and PURENERGY™ - IRVINE, Calif., Jan. 6, 2014 /PRNewswire/ -- ChromaDex Corporation® (OTCBB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has entered into a four year ingredient supply and brand licensing agreement valued at approximately $6... 
Printer Friendly Version
01/03/14ChromaDex® Appoints Former Nestle Executive to Its Board of Directors
IRVINE, Calif., Jan. 3, 2014 /PRNewswire/ --  ChromaDex® Corporation (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today an addition to its board of directors with the appointment of Steve Allen as an independent director.  Allen, age 64, has extensive experience in negotiating m... 
Printer Friendly Version